Long-Term Clinical Benefit of Sirolimus-Eluting Stents in Patients With In-Stent RestenosisResults of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) Study
Fernando Alfonso, MD*,*,
María-José Pérez-Vizcayno, MD*,
Rosana Hernández, MD*,
Armando Bethencourt, MD ,
Vicens Martí, MD ,
José R. López-Mínguez, MD ,
Juan Angel, MD||,
Andrés Iñiguez, MD¶,
César Morís, MD#,
Angel Cequier, MD**,
Manel Sabaté, MD ,
Javier Escaned, MD*,
Pilar Jiménez-Quevedo, MD*,
Camino Bañuelos, MD*,
Alfonso Suárez, MD*,
Carlos Macaya, MD* for the RIBS-II Investigators
* University Hospital, Clinico San Carlos, Madrid, Spain
University Hospital, Son Dureta, Palma de Mallorca, Spain
University Hospital, San Pablo, Barcelona, Spain
University Hospital, Infanta Cristina, Badajoz, Spain
|| University Hospital, Valle de Hebrón, Barcelona, Spain
¶ University Hospital, Meixoeiro, Vigo, Spain
# University Hospital, Central Asturias, Oviedo, Spain
** University Hospital, Bellvitge, Barcelona, Spain

View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Kaplan-Meier Estimates of Event-Free Survival
Kaplan-Meier estimates of event-free survival (death, myocardial infarction, and target vessel revascularization). Red line = sirolimus-eluting stent; blue line = balloon angioplasty.
|
|

View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Long-Term Clinical Outcome According to 10 Pre-Specified Variables
No patient with in-stent restenosis of a coil stent (1st ST Coil) was included. BA = balloon angioplasty; B/A = balloon-artery ratio; CI = confidence interval; LAD = left anterior descending coronary artery; RE = restenosis; SES = sirolimus-eluting stent.
|
|
|